PFEPfizerSigning up patients
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Cachexia · Metastatic Pancreatic Ductal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 982 (planned)
- Started
- Oct 3, 2025
- Main results expected
- Jan 23, 2028
- Fully finished
- Dec 24, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percent change from baseline in body weight for ponsegromab compared to placebo
Measured over: Baseline, Week 12
Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores
Measured over: Baseline, Week 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06989437 · record last updated 2026-10-14 · checked 2026-11-09 15:42 UTC